Drugs / DEPIGOID phleum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01634958 | Oct 2012 → Apr 2013 | allergic rhinitis | Leti Pharma GmbH | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02126111 Comparator | Oct 2010 → Apr 2016 | allergic rhinitis | Plaza del Hospital Civil | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Depigoid Phleum | “A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients With Allergic Rhinitis...” NCT01634958 ↗ |
| Known as | Depigoid 100% phleum | “The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum).” NCT02126111 ↗ |
| Modality | Other / unclassified | “4 concentrations of a modified pollen extract of Phleum pratense are applied” NCT01634958 ↗ |
| Route | Subcutaneous | “Suspension for subcutaneous injection” NCT01634958 ↗ |